Cite
Ikenaga H, Uchida-Kobayashi S, Tamori A, et al. Direct-acting antivirals reduce the risk of tumour progression of hepatocellular carcinoma after curative treatment. J Viral Hepat. 2021;doi: 10.1111/jvh.13627.
Ikenaga, H., Uchida-Kobayashi, S., Tamori, A., Odagiri, N., Yoshida, K., Kotani, K., Motoyama, H., Kozuka, R., Kawamura, E., Hagihara, A., Fujii, H., Enomoto, M., & Kawada, N. (2021). Direct-acting antivirals reduce the risk of tumour progression of hepatocellular carcinoma after curative treatment. Journal of viral hepatitis, . https://doi.org/10.1111/jvh.13627
Ikenaga, Hiroko, et al. "Direct-acting antivirals reduce the risk of tumour progression of hepatocellular carcinoma after curative treatment." Journal of viral hepatitis vol. (2021). doi: https://doi.org/10.1111/jvh.13627
Ikenaga H, Uchida-Kobayashi S, Tamori A, Odagiri N, Yoshida K, Kotani K, Motoyama H, Kozuka R, Kawamura E, Hagihara A, Fujii H, Enomoto M, Kawada N. Direct-acting antivirals reduce the risk of tumour progression of hepatocellular carcinoma after curative treatment. J Viral Hepat. 2021 Oct 25; doi: 10.1111/jvh.13627. Epub 2021 Oct 25. PMID: 34695288.
Copy
Download .nbib